FindTrial
Sign In

Elucidating the Role of Surfactant Protein D (SP-D) in Prostate Cancer

Elucidating the Role of Surfactant Protein D (SP-D) in Prostate Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2016/04/006890
Enrollment
15
Registered
2016-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Suspected metastatic prostate cancer patients.

Interventions

None listed

Sponsors

NIRRH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •Newly diagnosed patients with suspected metastatic prostate cancer [by clinical diagnosis and Ultrasound sonography (USG)] •High PSA levels ( > 10ng/ml) •Undergoing Prostate biopsy for their routine clinical care.

Exclusion criteria

Exclusion criteria: Prostate cancer patients undergoing •Chemotherapy, •Androgen deprivation therapy and •Radiotherapy will be excluded. •Therapy for any chronic ailment or infection

Design outcomes

Primary

MeasureTime frame
â?¢Anti-neoplastic role of Surfactant Protein D would be evaluated in primary cell cultures of prostate cancer patients for the first time.Timepoint: 36 months—

Secondary

MeasureTime frame
â?¢ The proposed study shall provide insights on expression and regulation of Surfactant Protein D in Prostate Cancer and its impact on the survival of prostate tumor cells. â?¢ Further, the study shall result in understanding of the putative interacting partners of SP-D in prostate cancer cells and the involved signal transduction pathways. Timepoint: 36 months—

Countries

India

Contacts

Public ContactDr Gagan Prakash

NIRRH

taruna_m@hotmail.com02224192106

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026